Schrödinger halted development of SGR-2921, a cell division cycle 7 (CDC7) inhibitor for acute myeloid leukemia and high-risk myelodysplastic syndromes, following two patient deaths linked to the drug during a Phase I dose-escalation study. The company acknowledged early signs of monotherapy activity but deemed further development unsafe given the mortality and adverse profile observed. This decision underscores ongoing challenges in developing CDC7-targeted therapies for blood cancers.